sTRAIL-iRGD is a promising therapeutic agent for gastric cancer treatment

por Ying Huang, Xihan Li, Huizi Sha, Lianru Zhang, Xinyu Bian, Xiao Han, Baorui Liu
Publicado 2017

iRGD synergizes with PD-1 knockout immunotherapy by enhancing lymphocyte infiltration in gastric cancer

por Naiqing Ding, Zhengyun Zou, Huizi Sha, Shu Su, Hanqing Qian, Fanyan Meng, Fangjun Chen, Shiyao Du, Shujuan Zhou, Hong Chen, Lianru Zhang, Ju Yang, Jia Wei, Baorui Liu
Publicado 2019